![Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401 Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401](https://fccid.io/images/device/2AJVS/PDR0000401/External-Photos-1246BBA1.jpg)
Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401
![TEVA Pharmaceutical Industries Ltd. | Pharmaceutical Outsourcing - The Journal of Pharmaceutical & Biopharmaceutical Contract Services TEVA Pharmaceutical Industries Ltd. | Pharmaceutical Outsourcing - The Journal of Pharmaceutical & Biopharmaceutical Contract Services](https://media.pharmoutsourcing.com/m/30/vendor/106308.jpg)
TEVA Pharmaceutical Industries Ltd. | Pharmaceutical Outsourcing - The Journal of Pharmaceutical & Biopharmaceutical Contract Services
![Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401 Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401](https://cdn-0.fccid.io/images/device/2AJVS/PDR0000401/Internal-Photos-645EADB6.jpg)
Teva Branded Pharmaceutical Products R&D;, . An electronic inhaler add-on module which store and transmit information related to inhaler use (eModule) PDR0000401 FCC ID 2AJVSPDR0000401
![PDF) Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors PDF) Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors](https://i1.rgstatic.net/publication/262784686_Phase_1_dose-escalation_study_of_the_PARP_inhibitor_CEP-9722_as_monotherapy_or_in_combination_with_temozolomide_in_patients_with_solid_tumors/links/549d0f070cf2b8037138c9c9/largepreview.png)
PDF) Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
![Branded Generics Market Services Grow at a 7.3% CAGR From – Mylan N.V, Novartis AG, Teva Pharmaceutical Industries Ltd | Medgadget Branded Generics Market Services Grow at a 7.3% CAGR From – Mylan N.V, Novartis AG, Teva Pharmaceutical Industries Ltd | Medgadget](https://www.medgadget.com/wp-content/uploads/2021/10/branded-generics-market.jpg)